Shortage of Dexmedetomidine Hydrochloride Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Dexmedetomidine Hydrochloride Injection, with some manufacturers unavailable while others continue to supply it.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dexmedetomidine Hydrochloride Injection.
Dexmedetomidine Hydrochloride Injection Shortage
We understand that drug shortages can be concerning, especially for those who depend on this medication for critical care. This article provides factual information based on the latest available data.
What's in Shortage
The generic drug is Dexmedetomidine Hydrochloride Injection, with brand names including PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE, and others. It is available in injection dosage form and falls under the anesthesia therapeutic category. The shortage status is current, with the initial posting date of April 10, 2020, and last updated on April 1, 2026.
Which Manufacturers Are Affected
Several manufacturers are involved, with varying availability:
- HQ Specialty Pharma: Available, marketed by WG Critical Care, contact: 888-493-0861
- Fresenius Kabi USA, LLC: Unavailable for multiple presentations, expected recovery: TBD, contact: 888-386-1300
- Baxter Healthcare: Available for some presentations (e.g., 400 ug/100 mL), unavailable for others (e.g., 200 ug/50 mL, estimated recovery: April 2026), contact: 888-229-0001
- Pfizer Inc.: Available for various presentations, contact: 844-646-4398
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Available, marketed by Sandoz Inc. or Avenacy, customer service: 800-525-8747 or 877-283-6229
- Mylan Institutional, a Viatris Company: Available, contact: 800-796-9526
Why There's a Shortage
No specific reason was given for this shortage.
What Patients Should Do
If you are affected by this shortage, we recommend talking to your pharmacist or healthcare provider to check availability and discuss options. You may also contact the relevant manufacturer for updates. Please remember that patients should always consult their healthcare provider for any medical advice or changes to their treatment.
Source
This information is sourced from the FDA Drug Shortage Database, initially posted on April 10, 2020, and last updated on April 1, 2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,975 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.